In the high-stakes world of pharmaceutical research, the journey from laboratory bench to pharmacy shelf is fraught with failure. However, a significant portion of these "failures" has nothing to do with medical efficacy. According to Annette Bakker, PhD, CEO of the Children’s Tumor Foundation (CTF), more than 5,000 potential rare disease treatments currently sit dormant on the shelves of major pharmaceutical companies. These are not necessarily ineffective compounds; they are often the victims of corporate restructuring, shifting portfolio priorities, or the collapse of small biotech partners.
For the millions of patients living with rare conditions, these "shelved assets" represent a tragic missed opportunity. Now, the CTF is leading a crusade to rescue these abandoned programs, transforming them from corporate write-offs into life-saving therapies.
The Anatomy of a Shelved Asset: Why Good Science Gets Stalled
To understand the scale of the problem, one must understand the economic realities of modern drug development. Pharmaceutical companies often operate on a "blockbuster" model, prioritizing drugs that address mass-market conditions. When a major firm acquires a smaller biotech, it is frequently to secure one "crown jewel" asset. The secondary or tertiary candidates in that biotech’s pipeline—which might show immense promise for rare, niche conditions—are often discarded, not because they are unsafe or ineffective, but because they do not fit the parent company’s strategic focus.
The "Data Graveyard" Phenomenon
When a project is shelved, the consequences for the scientific community are severe. Often, the extensive preclinical, toxicology, and Phase 1 data generated at a cost of hundreds of millions of dollars are locked away in corporate servers, never to be seen again. If a biotech company goes bankrupt or undergoes a merger, that intellectual property effectively enters a "data graveyard."
"Shelved assets are our focus because a shelved asset has already undergone a lot of development," Dr. Bakker explains. "A company has maybe already spent hundreds of millions of dollars on them, and they are now written off as a loss. What if we could take those and put them right into clinical trials? We could win all those years of preclinical and toxicology work and go into clinical almost immediately."
Chronology of a Success Story: The Path to Gomekli
The model for this "rescue" strategy is best illustrated by the success of Gomekli (selumetinib), a treatment for neurofibromatosis (NF)—a group of genetic conditions causing tumors to grow on nerves throughout the body.
2017: The Catalyst
The Children’s Tumor Foundation acted as a catalyst, identifying MEK inhibitors as a viable therapeutic pathway for NF patients. Recognizing the potential of a shelved Pfizer asset, Dr. Bakker engaged in high-level discussions with Pfizer executives Freda Lewis-Hall and Lara Sullivan. These internal champions recognized the value in the data, leading to the licensing of the drug to a newly formed spin-off, SpringWorks Therapeutics.
2023: FDA Approval and Market Validation
The strategy bore fruit when the FDA approved Gomekli as a treatment for inoperable plexiform neurofibromas. The validation of this model was cemented when Merck KGaA acquired SpringWorks Therapeutics for $3.4 billion. This transition proved that an asset written off by a larger entity could be rescued, developed, and brought to market through a collaborative, non-profit-led ecosystem.
Supporting Data: The Rare Disease Disadvantage
The challenges inherent in rare disease research are exponential. As Dr. Bakker notes, "Everything you do in drug discovery is ten times harder in rare disease."
Patient Recruitment Hurdles
Rare diseases, by definition, affect a small number of people. With NF affecting roughly 1 in 2,000 people, finding a sufficient cohort for a clinical trial is a logistical nightmare. When patients are scattered across different countries, the costs and timelines for traditional trial recruitment skyrocket.
The CTF Infrastructure
To combat this, the CTF has developed a sophisticated infrastructure designed to lower these barriers:
- The Preclinical Hub: A robust, growing network of preclinical models that allows for rapid testing of rescued compounds.
- Patient Networks: By leveraging their deep connection to the patient community, the CTF acts as a recruitment engine, significantly shortening the time it takes to fill clinical trial quotas.
- Integrated Ecosystems: The foundation aims to create a "plug-and-play" environment where a rescued drug can move from the shelf to the lab, and then to the clinic, with minimal friction.
Official Responses and the Corporate Barrier
While the success of Gomekli serves as a powerful proof-of-concept, scaling this model remains the greatest obstacle. Dr. Bakker acknowledges that despite the clear benefits, the foundation faces significant resistance.
"We are looking for these champions in other companies that are willing to work with us," Dr. Bakker says. "But the pharma companies we are calling are not opening the door."
This resistance often stems from corporate risk aversion. Even when a drug is a "write-off," companies may be reluctant to release the asset due to liability concerns, internal legal hurdles, or the fear that a third party might find success with a drug they deemed a failure, potentially reflecting poorly on their own internal decision-making.
The CTF is currently advocating for a cultural shift within the pharmaceutical industry—one that prioritizes "asset recycling" and open-science collaboration for the sake of patient outcomes.
Implications: A New Era of Drug Discovery
The implications of the CTF’s work extend far beyond neurofibromatosis. If this model can be applied to other therapeutic areas, it could effectively unlock a new frontier of medicine.
1. Accelerating Time-to-Market
By skipping the discovery and early-stage toxicology phases, the time required to bring a drug to market can be reduced by several years. For patients with progressive, life-threatening rare diseases, these years are the difference between life and death.
2. Economic Efficiency
Billions of dollars are currently tied up in "zombie" assets. By facilitating the transfer of these assets to specialized foundations or spin-offs, the industry can recover value from sunken costs, potentially reinvesting those resources into new R&D.
3. Fostering Collaboration
The CTF model necessitates a new type of partnership between non-profits, academia, and Big Pharma. This "Triple Helix" approach—where patient advocacy groups lead, academia provides the scientific rigor, and pharma provides the foundational assets—could redefine the standard for rare disease drug development.
4. Patient Empowerment
Finally, this model puts patients at the center of the process. Rather than being passive recipients of the industry’s focus, rare disease foundations are becoming the architects of their own therapeutic pipelines.
Conclusion
The Children’s Tumor Foundation has identified a massive systemic inefficiency in the pharmaceutical industry. By treating shelved assets not as failures, but as overlooked opportunities, they are demonstrating that the cure for many rare diseases may already exist—it is simply waiting for someone to unlock the door.
As the foundation continues to lobby for better access to these "forgotten" compounds, the hope is that more pharmaceutical giants will recognize that their discarded assets could be the foundation’s next breakthrough. In the race against rare disease, the most efficient path forward may not be to invent something new, but to rescue what has already been found.
About the Author
